BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37553713)

  • 21. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma.
    Wang S; Xiao F; Sun W; Yang C; Ma C; Huang Y; Xu D; Li L; Chen J; Li H; Xu H
    Front Neurosci; 2021; 15():791776. PubMed ID: 35153659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
    Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
    Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
    Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
    JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
    Oh S; Yeom J; Cho HJ; Kim JH; Yoon SJ; Kim H; Sa JK; Ju S; Lee H; Oh MJ; Lee W; Kwon Y; Li H; Choi S; Han JH; Chang JH; Choi E; Kim J; Her NG; Kim SH; Kang SG; Paek E; Nam DH; Lee C; Kim HS
    Nat Commun; 2020 Jul; 11(1):3288. PubMed ID: 32620753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteomics-based prognostic signature and nomogram construction of hypoxia microenvironment on deteriorating glioblastoma (GBM) pathogenesis.
    Wen YD; Zhu XS; Li DJ; Zhao Q; Cheng Q; Peng Y
    Sci Rep; 2021 Aug; 11(1):17170. PubMed ID: 34446747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
    Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
    J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
    Tini P; Yavoroska M; Mazzei MA; Miracco C; Pirtoli L; Tomaciello M; Marampon F; Minniti G
    J Neurooncol; 2023 Jun; 163(2):339-344. PubMed ID: 37227648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel risk signature with 6 RNA binding proteins for prognosis prediction in patients with glioblastoma.
    Huang QR; Li JW; Pan XB
    Medicine (Baltimore); 2021 Dec; 100(48):e28065. PubMed ID: 35049227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of a nomogram with an autophagy-related gene signature for predicting survival in patients with glioblastoma.
    Wang Z; Gao L; Guo X; Feng C; Lian W; Deng K; Xing B
    Aging (Albany NY); 2019 Dec; 11(24):12246-12269. PubMed ID: 31844032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. neoDL: a novel neoantigen intrinsic feature-based deep learning model identifies IDH wild-type glioblastomas with the longest survival.
    Sun T; He Y; Li W; Liu G; Li L; Wang L; Xiao Z; Han X; Wen H; Liu Y; Chen Y; Wang H; Li J; Fan Y; Zhang W; Zhang J
    BMC Bioinformatics; 2021 Jul; 22(1):382. PubMed ID: 34301201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Large-Scale Analysis Reveals Gene Signature for Survival Prediction in Primary Glioblastoma.
    Prasad B; Tian Y; Li X
    Mol Neurobiol; 2020 Dec; 57(12):5235-5246. PubMed ID: 32875483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
    Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
    J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery.
    Tan Y; Zhang ST; Wei JW; Dong D; Wang XC; Yang GQ; Tian J; Zhang H
    Eur Radiol; 2019 Jul; 29(7):3325-3337. PubMed ID: 30972543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.